{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:15:41Z","timestamp":1788225341877,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009729","name":"Ludwig Institute for Cancer Research Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009729","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.isci.2026.116587","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:50:15Z","timestamp":1782791415000},"page":"116587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reversal of T cell exhaustion enables cancer vaccine efficacy in BRCA1-deficient ovarian cancer"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8526-3261","authenticated-orcid":false,"given":"Laurent","family":"Beziaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0063-2513","authenticated-orcid":false,"given":"Aspram","family":"Minasyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl L-L","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania M.","family":"Soukarieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde M.","family":"Coppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Rovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Thevenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Tissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denarda","family":"Dangaj-Laniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana E.","family":"Kandalaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.116587_bib1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/JS9.0000000000003398","article-title":"Global, regional, and national burden of ovarian cancer, 1990-2021, and projections to 2050: a cross-sectional analysis of the global burden of disease study 2021","volume":"112","author":"Xie","year":"2026","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.isci.2026.116587_bib2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2026.116587_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40364-025-00818-7","article-title":"Therapeutic landscape of ovarian cancer: recent advances and emerging therapies","volume":"13","author":"Wang","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.isci.2026.116587_bib4","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1200\/JCO.22.01934","article-title":"and for the PARP Inhibitors in the Management of Ovarian Cancer Guideline Expert Panel (2022). Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update","volume":"40","author":"Tew","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.116587_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.116587_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.116587_bib7","article-title":"Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer","volume":"3","author":"Goode","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2026.116587_bib8","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.116587_bib9","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41467-022-28389-3","article-title":"Single-cell tumor-immune microenvironment of BRCA1\/2 mutated high-grade serous ovarian cancer","volume":"13","author":"Launonen","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.116587_bib10","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41568-022-00503-z","article-title":"Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation","volume":"22","author":"Kandalaft","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.isci.2026.116587_bib11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41571-024-00937-4","article-title":"Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach","volume":"21","author":"Ghisoni","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.116587_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao5931","article-title":"Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer","volume":"10","author":"Tanyi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.116587_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41541-021-00297-5","article-title":"Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer","volume":"6","author":"Tanyi","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.isci.2026.116587_bib14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s12967-019-02133-w","article-title":"A Phase I\/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma","volume":"17","author":"Sarivalasis","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.isci.2026.116587_bib15","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/0008-5472.CAN-16-1272","article-title":"CRISPR\/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma","volume":"76","author":"Walton","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.116587_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17119-1","article-title":"CRISPR\/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity","volume":"7","author":"Walton","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.116587_bib17","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.116587_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109412","article-title":"Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING","volume":"36","author":"Bruand","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.116587_bib19","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.ccell.2021.10.008","article-title":"Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation","volume":"39","author":"Duraiswamy","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.116587_bib20","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","article-title":"Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment","volume":"174","author":"Azizi","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.116587_bib21","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","article-title":"A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade","volume":"175","author":"Jerby-Arnon","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.116587_bib22","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8+ T cell states in human cancer: insights from single-cell analysis","volume":"20","author":"van der Leun","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.isci.2026.116587_bib23","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/s43018-020-00139-8","article-title":"Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy","volume":"1","author":"Samstein","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.isci.2026.116587_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009058","article-title":"Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8+ TILs based on BRCA1\/2 mutation status in epithelial ovarian cancers","volume":"12","author":"Park","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.116587_bib25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13578-023-01138-9","article-title":"Glycolysis-cholesterol metabolic axis in immuno-oncology microenvironment: emerging role in immune cells and immunosuppressive signaling","volume":"13","author":"Jin","year":"2023","journal-title":"Cell Biosci."},{"key":"10.1016\/j.isci.2026.116587_bib26","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming Grown Factor-\u03b2 Signaling in Immunity and Cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2026.116587_bib27","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00262-017-2019-6","article-title":"Endoplasmic reticulum stress regulates tumor growth and anti-tumor immunity: a promising opportunity for cancer immunotherapy","volume":"66","author":"Mohamed","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.isci.2026.116587_bib28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ygyno.2025.02.010","article-title":"Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis","volume":"194","author":"Alvero","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.isci.2026.116587_bib29","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.ccell.2025.07.005","article-title":"Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer","volume":"43","author":"Ghisoni","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.116587_bib30","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1111\/jcmm.13678","article-title":"Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma","volume":"22","author":"Dai","year":"2018","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.isci.2026.116587_bib31","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1158\/2159-8290.CD-18-1357","article-title":"Cancer vaccines: Steering T cells down the right path to eradicate tumors","volume":"9","author":"Ott","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.116587_bib32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s40425-019-0641-x","article-title":"Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer","volume":"7","author":"McGray","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.116587_bib33","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1158\/0008-5472.CAN-12-4100","article-title":"Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors","volume":"73","author":"Duraiswamy","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.116587_bib34","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1158\/0008-5472.CAN-13-1550","article-title":"Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer","volume":"73","author":"Duraiswamy","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.116587_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007661","article-title":"Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade","volume":"11","author":"Luo","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.116587_bib36","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1038\/s41467-020-18962-z","article-title":"Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients","volume":"11","author":"Block","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.116587_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000829","article-title":"Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial","volume":"8","author":"Zamarin","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.116587_bib38","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1080\/14796694.2024.2386922","article-title":"TEDOVA: vaccine OSE2101 +\/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer","volume":"20","author":"Kabirian","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.isci.2026.116587_bib39","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.116587_bib40","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/2326-6066.CIR-15-0044","article-title":"CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer","volume":"3","author":"Higuchi","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.isci.2026.116587_bib41","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.1038\/s41467-023-40829-2","article-title":"Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01\/APGOT-OV4","volume":"14","author":"Kim","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.116587_bib42","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1038\/s41467-024-45974-w","article-title":"Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group","volume":"15","author":"Freyer","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.116587_bib43","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1158\/1078-0432.CCR-13-1185","article-title":"A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside","volume":"19","author":"Chiang","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.116587_bib44","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.116587_bib45","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.isci.2026.116587_bib46","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41592-023-02014-7","article-title":"Extending support for mouse data in the Molecular Signatures Database (MSigDB)","volume":"20","author":"Castanza","year":"2023","journal-title":"Nat. Methods"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226019620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226019620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:52:39Z","timestamp":1788223959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226019620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2589004226019620"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.116587","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversal of T cell exhaustion enables cancer vaccine efficacy in BRCA1-deficient ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.116587","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116587"}}